Highplex imaging with the Orion platform for clinical trial testing

Dr. Richard Van Krieken (Senior Scientist, Navigate BioPharma Services) presents a novel high-plex assay using the Orion platform for advanced immune profiling in cancer. This assay detects 16 antibodies plus a nuclear stain simultaneously in FFPE tissues, overcoming traditional immunohistochemistry limits like small marker panels and tissue damage from repeated staining. Applicable to breast, lung, prostate, melanoma, and colorectal cancers, it offers deeper insights into tumor-immune interactions and resistance mechanisms. This technology aims to enhance patient stratification and treatment decisions while conserving precious tissue samples.